Qinoline derivatives inhibiting effect of growth factors such as VEGF

Compounds of the formula (I):wherein: R represents hydroxy, halogeno, C1-3alkyl, C1-3alkoxy, C1-3alkanoyloxy, trifluoromethyl, cyano, amino or nitro; n is an integer from 0 to 5; Z represents -O-, -NH-, -S- or -CH2-; G represents phenyl or a 5-10 membered heteroaromatic cyclic or bicyclic group; Y , Y , Y and Y each independently represents carbon or nitrogen; R represents fluoro or hydrogen; m is an integer from 1 to 3; R represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C1-3alkyl, -NR R (wherein R and R , can each be hydrogen or C1-3alkyl), or a group R -X - wherein X represents -CH2- or a heteroatom linker group and R is an alkyl, alkenyl or alkynyl chain optionally substituted by for example hydroxy, amino, nitro, alkyl, cycloalkyl, alkoxyalkyl, or an optionally substituted group selected from pyridone, phenyl and a heterocyclic ring, which alkyl, alkenyl or alkynyl chain may have a heteroatom linker group, or R is an optionally substituted group selected from pyridone, phenyl and a heterocyclic ring and salts thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals such as humans, processes for the preparation of such derivatives, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient and compounds of formula I. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.